Wave, Duchenne muscular dystrophy
Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced today the pricing of its previously announced underwritten public offering of 23,
Wave Life Sciences Shares Climb Premarket on Duchenne Study Data
Shares of Wave Life Sciences rose more than 10% in premarket trading Tuesday after the clinical-stage biotechnology company reported positive interim data from a mid-stage study of its WVE-N531 drug candidate in the neuromuscular genetic disease Duchenne muscular dystrophy.
Surfing on new Duchenne data, Wave charges $175m offering
Shares in Wave rose 53% after the trial data was announced, taking its market cap above the $1 billion threshold. The company has moved swiftly ahead with a public offering, seeking to raise an estimated $175 million as it moves towards possible commercialisation of WVE-N531.
Wave Life Sciences: Spiking On Strong DMD Data, But Not Fully De-Risked Yet
Wave Life Sciences stock surged over 50% today due to promising data from its Duchenne Muscular Dystrophy candidate WVE-N531. Explore more details here.
Wave Life Sciences’ stock soars 51% after biotech posts positive data from Duchenne muscular-dystrophy trial
Biotech reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne muscular dystrophy.
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to ...
Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
The Federal Reserve rate cuts have sent the market up, but some stocks are rising more than others. That includes small pharmaceutical companies like Wave Life Sciences (NASDAQ: WVE), whose shares ...
Wave Life Sciences gains on data for Duchenne therapy
Wave Life Sciences (NASDAQ:WVE) added ~8% premarket Tuesday after the RNA therapeutics company announced interim data from a ...
Wave Life Sciences’ Strong Clinical Data and Market Potential Merit Buy Rating
Mizuho Securities analyst Salim Syed has maintained their bullish stance on WVE stock, giving a Buy rating today. Salim Syed has given his Buy ...
The Pharma Letter1d
Wave Life Sciences soars on positive DMD trial results
Wave Life Sciences has announced positive interim data from the ongoing Phase II FORWARD-53 study of WVE-N531, which is an ...
FierceBiotech2d
Wave surfs DMD success to regulators' doors, sending stock up
Wave’s result is in line with the data that supported accelerated approval of NS Pharma’s exon 53 DMD drug Viltepso. NS ...
Wave Life Sciences (WVE) Gets a Buy from Truist Financial
In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Wave Life Sciences (WVE – Research Report). The ...
Yahoo Finance1d
Wave’s stock swells as it eyes approval following Phase II DMD victory
Wave Life Sciences is eyeing an accelerated approval for its Duchenne muscular dystrophy (DMD) drug, with the company’s ...